- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Sanofi’s Dupixent website hosted a NICE guidance resource with Oct 2017 prescribing information and an HCP guide stating asthma safety/efficacy not established.…
A Pfizer UK employee ‘liked’ a Global Pfizer LinkedIn post about interim vaccine efficacy before authorisation. The Panel said this proactively disseminated…
Brintellix webinar registration page was promotional but lacked prescribing info and AE reporting statement. A global colleague changed the job code after…
Ever Pharma’s Dacepton materials were ruled misleading where stability and cost-saving claims omitted microbiological contamination caveats and key dosing context. Several other…
Two BI employees ‘liked’ a LinkedIn news post about an investigational SARS‑CoV‑2 neutralising antibody entering Phase 1/2a. Panel found the activity in…
Ex-employee alleged Allergan product specialists promoted Botox via Instagram tags/hashtags linking to HCP/clinic posts. Panel found breaches, but Appeal Board overturned due…
A Lixiana (edoxaban) print journal ad was cleared on imagery and dosing allegations, but breached the Code for failing to signpost that…
Otsuka Europe admitted it missed SOP timelines to notify affiliates of a Samsca SPC update and delayed updated prescribing information. PMCPA ruled…
Eliquis HCP site banner ‘Choose Eliquis’ was not misleading, but the adverse event reporting statement wasn’t included within the promotional pages themselves—breach…
Employee complaint: pressure to boost activity led to guidance to log emails as calls, unclear call vs contact briefings, HCP prep work…
LEO made a voluntary admission after five 2020 transfers of value (4 HCP, 1 HCO) were omitted from its UK Disclosure UK…
PMCPA found multiple breaches on LEO’s Kyntheum HCP website, including misleading/exaggerated claims and unbalanced safety messaging (Clause 2 at several points). Appeals…
PMCPA found Daiichi Sankyo’s Lixiana HCP mobile homepage made prescribing info and AE reporting insufficiently prominent by placing them behind an expandable…
Polivy dosing webpage gave the impression it contained all key administration info, but omitted SPC instructions on a dedicated infusion line/filter and…
Novartis’ HCP website claim “THINK Symptom-free” for Xolair in CSU was ruled misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). Other claims (“UNLOCK…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.